Adriano Venditti explains how you can get involved with the virtual AML Hub Satellite Symposium

The AML Hub will hold a virtual satellite symposium at the 46th Annual Meeting of the European Society...

AML Hub Satellite Symposium: How does MRD impact outcome of stem cell transplantation in AML, now and in the future?

At the 46th Annual Meeting of the European Society for Blood and Marrow...

Jacqueline Cloos explains how you can get involved with the virtual AML Hub Satellite Symposium

The AML Hub will hold a virtual satellite symposium at the 46th Annual Meeting of the European Society...

Molecular MRD status as a predictor of outcome in patients with NPM1-mutated acute myeloid leukemia (AML)

Measurable residual disease (MRD) assessed prior to allogeneic hematopoietic stem cell...

Molecular landscape and prognostic impact of FLT3-ITD insertion site in AML: An analysis of the RATIFY study

During an oral abstract session at the Virtual Edition of the 25th European Hematology...

Emerging mutations at relapse in patients with FLT3-muated R/R AML who were treated with gilteritinib in the ADMIRAL trial

During an oral abstract session at the 25th European Hematology Association...

NICE supports gilteritinib for adults with relapsed/refractory FLT3-mutated AML

The National Institute for Health and Care Excellence (NICE) have released the final appraisal document for the...

How close are we to offering treatment tailored to mutational profile?

During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to...

APR-246 plus azacitidine for patients with TP53 mutated MDS and AML

The GFM-APR trial is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients with TP53 mutant...

Can CD47 antibody therapy be safely used for AML and MDS?

Podcast discussion between David Sallman, Moffitt Cancer Center, and Naval Daver, MD Anderson Cancer Center, held during the 25th Congress of...

The role of the Nlrp3 inflammasome in hematological pathologies

The Nlrp3 inflammasome has recently gained a lot of attention due to its reported involvement in various hematological pathologies,...

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak...